Siltuximab: meta-analysis of COVID-19 studies

All studies   Mortality   Serious outcomes   RCTs   RCT mortality   Peer-reviewed   All outcomes  
Meta-analysis1 study · 149 patientsc19early.org

Siltuximab for COVID-19

Serious outcome risk
Siltuximab
Control
Outcome (studies)
Improvement
Relative risk · 95% CI
All studies (1)−64%
Mortality (1)−64%
RCTs (1)−64%
Late (1)−64%
00.511.5+
← Siltuximab
reduces riskIncreased
risk →
c19early.org
October 2026

Siltuximab COVID-19 studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Declercq (RCT)−64%1.64 · 0.77–3.52death15/759/74COV-AID
Late treatment−64%1.64 · 0.77–3.5215/759/7464% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.2
All studies−64%1.64 · 0.77–3.5215/759/7464% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.200.511.52+
Rotate screen for more detailsIncrease width for more details
← Siltuximab
reduces riskSiltuximab
increases risk →
c19early.org
October 2026

Siltuximab COVID-19 mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Declercq (RCT)−64%1.64 · 0.77–3.5215/759/74COV-AID
Late treatment−64%1.64 · 0.77–3.5215/759/7464% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.2
All studies−64%1.64 · 0.77–3.5215/759/7464% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.200.511.52+
Rotate screen for more detailsIncrease width for more details
← Siltuximab
reduces riskSiltuximab
increases risk →
c19early.org
October 2026

Siltuximab COVID-19 serious outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Declercq (RCT)−64%1.64 · 0.77–3.52death15/759/74COV-AID
Late treatment−64%1.64 · 0.77–3.5215/759/7464% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.2
All studies−64%1.64 · 0.77–3.5215/759/7464% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.200.511.52+
Rotate screen for more detailsIncrease width for more details
← Siltuximab
reduces riskSiltuximab
increases risk →
c19early.org
October 2026

Siltuximab COVID-19 Randomized Controlled Trials

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Declercq (RCT)−64%1.64 · 0.77–3.52death15/759/74COV-AID
Late treatment−64%1.64 · 0.77–3.5215/759/7464% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.2
All studies−64%1.64 · 0.77–3.5215/759/7464% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.200.511.52+
Rotate screen for more detailsIncrease width for more details
← Siltuximab
reduces riskSiltuximab
increases risk →
c19early.org
October 2026

Siltuximab COVID-19 RCT mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Declercq (RCT)−64%1.64 · 0.77–3.5215/759/74COV-AID
Late treatment−64%1.64 · 0.77–3.5215/759/7464% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.2
All studies−64%1.64 · 0.77–3.5215/759/7464% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.200.511.52+
Rotate screen for more detailsIncrease width for more details
← Siltuximab
reduces riskSiltuximab
increases risk →
c19early.org
October 2026

Siltuximab COVID-19 peer reviewed studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Declercq (RCT)−64%1.64 · 0.77–3.52death15/759/74COV-AID
Late treatment−64%1.64 · 0.77–3.5215/759/7464% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.2
All studies−64%1.64 · 0.77–3.5215/759/7464% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.200.511.52+
Rotate screen for more detailsIncrease width for more details
← Siltuximab
reduces riskSiltuximab
increases risk →